University of Poitiers

FIRE-4.5 study compared FOLFOXIRI plus cetuximab vs. bevacizumab in BRAFV600E-mutant mCRC. ORR was 51% vs. 67%, favoring bevacizumab. PFS was significantly shorter with cetuximab (6.7 vs. 10.7 months). Bevacizumab-based therapy remains preferable for first-line treatment.